UPDATE: LUNAR Trial Follow-Up Strengthens Case for Earlier PSMA Radioligand Therapy

/in , , /by

Longer follow-up from the randomized phase 2 LUNAR trial suggests that PSMA-targeted radioligand therapy may do more than simply delay progression when used early in men with oligorecurrent hormone-sensitive prostate cancer. LUNAR enrolled 92 men whose prostate cancer had returned after previous treatment, with one to five metastases visible on PSMA PET/CT. Importantly, patients were […]

Read more

Doxycycline Shows Preclinical Activity Against Prostate Cancer Bone Metastasis

/in , /by

A new preclinical study suggests that doxycycline, a widely used antibiotic, may help interfere with the process that allows prostate cancer cells to spread and grow in bone. The researchers identified acetylated KLF5 (Ac-KLF5) as an important driver of bone metastasis. This altered form of KLF5 appears to make prostate cancer cells more invasive and […]

Read more

New Randomized Phase 2 Trial Tests Vaccine Plus PSMA×CD3 Immunotherapy in Biochemical Recurrence

/in , , /by

A new randomized phase 2 trial will test an immunotherapy strategy specifically in men with biochemical recurrence of prostate cancer after local treatment with curative intent, meaning patients whose PSA is rising again after surgery and/or radiotherapy but who are not yet receiving further systemic treatment. The study plans to enrol up to 84 patients […]

Read more

UPDATE: VIR-5500 Receives FDA Fast Track Designation Following Promising Phase 1 Results in mCRPC / mAPMR

/in , , /by

The US Food and Drug Administration (FDA) has granted Fast Track designation to VIR-5500 (formerly AMX-500), an experimental immunotherapy for patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). The designation is intended to accelerate clinical development and regulatory review, but does not constitute drug approval. VIR-5500 is a bispecific T-cell engager designed to direct […]

Read more

Phase 1 Trial for KMV002, a New Prostate Cancer Vaccine for mCRPC

/in , , /by

A new phase 1  clinical trial will investigate KMV002, an experimental therapeutic cancer vaccine for patients with metastatic prostate cancer that has become resistant to androgen-targeting treatments (mAPMR, previously mCRPC). Patients will receive either five or six doses of KMV002, a combination of SN3001C and an immune-stimulating substance known as a CpG ODN adjuvant. KMV002, […]

Read more

Can One tRNA Reverse Hormone Resistance in Prostate Cancer?

/in /by

A new study published in Nature has identified a single transfer RNA, tRNA1Arg(UCU) as an important regulator of prostate cancer behaviour and resistance to hormone therapy. The researchers found that this tRNA is relatively abundant in androgen receptor-driven prostate cancer, but falls as tumours become more aggressive, more plastic and more neuroendocrine-like. In samples from […]

Read more

UPDATE: ENV-105 Extends Median PFS to 17.7 Months in mCRPC

/in , , /by

We updated you about the positive results of carotuximab (ENV-105) in this previous post. Now phase 2 data suggest that ENV-105 combined with apalutamide may substantially delay progression in metastatic castration-resistant prostate cancer (mCRPC) compared with apalutamide alone. In the randomised study, median progression-free survival reached 17.7 months with ENV-105 plus apalutamide, compared with just […]

Read more

Can We Make Metastatic Prostate Cancer Cells Fragile Again?

/in /by

Metastasis requires more than the ability to grow. Tumor cells that enter the bloodstream must also survive powerful mechanical forces that can physically damage or destroy them. A new preclinical study suggests that prostate cancer cells can adapt to this stress, and identifies CALB2 as a possible weak point in that adaptation. Researchers repeatedly exposed […]

Read more